Anhui Fengyuan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anhui Fengyuan Pharmaceutical CEO'su Tianle Ru, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. şirketin hisselerinin 0.3% doğrudan sahiptir ve bu hisselerin değeri CN¥ 8.90M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.7 yıl ve 5.4 yıldır.

Anahtar bilgiler

Tianle Ru

İcra Kurulu Başkanı

CN¥862.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	7.7yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

May 07

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Apr 17

CEO

Tianle Ru (39 yo)

2.3yrs

Görev süresi

CN¥862,000

Tazminat

Mr. Tianle Ru is General Manager and Director of Anhui Fengyuan Pharmaceutical Co., Ltd since July 07, 2022.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tianle Ru	GM & Director	2.3yrs	CN¥862.00k	0.30% CN¥ 8.9m
Jun Li	Deputy GM & Financial Director	7.7yrs	CN¥420.00k	0.12% CN¥ 3.5m
Shaoyi Zhang	Deputy GM & Director	17.6yrs	CN¥588.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	4.2yrs	CN¥354.00k	0.11% CN¥ 3.1m
Jun Zhang	Secretary of the Board & Non-Independent Director	26.1yrs	CN¥336.00k	0.14% CN¥ 4.0m
Guo Kun Li	Deputy General Manager	11.6yrs	CN¥392.00k	0.060% CN¥ 1.8m
Shuang Qing Yin	Deputy General Manager	5.4yrs	CN¥380.00k	0.090% CN¥ 2.7m

7.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 000153 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tianle Ru	GM & Director	2.3yrs	CN¥862.00k	0.30% CN¥ 8.9m
Shaoyi Zhang	Deputy GM & Director	10.1yrs	CN¥588.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	8.7yrs	CN¥354.00k	0.11% CN¥ 3.1m
Jun Zhang	Secretary of the Board & Non-Independent Director	4.5yrs	CN¥336.00k	0.14% CN¥ 4.0m
Hongman He	Chairman of the Board	16.7yrs	CN¥920.00k	0.45% CN¥ 13.4m
Yue'e Hu	Chairman of Supervisory Board	2.3yrs	CN¥420.00k	Veri yok
Weidong Zhu	Independent Director	5.4yrs	CN¥60.00k	Veri yok
Jiemiao Chen	Independent Director	5.4yrs	CN¥60.00k	Veri yok
Jinsheng Hu	Non-Employee Supervisor	5.4yrs	Veri yok	Veri yok
Jinchao Duan	Director	2.3yrs	CN¥344.00k	0.060% CN¥ 1.8m
Cisheng Wu	Independent Director	2.3yrs	CN¥60.00k	Veri yok
Hui Yan Sun	Supervisor	5.4yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000153 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Anhui Fengyuan Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

High number of new directors

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.085 in 3Q 2023)

Investor sentiment improves as stock rises 16%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 21%

Now 22% overvalued after recent price rise

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dividend increased to CN¥0.15

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 07 June 2024

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Now 23% overvalued

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2022)

Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.37 in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 2Q 2021)

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022

Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.041 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.26 in FY 2019)

Investor sentiment improved over the past week

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥6.62

Investor sentiment deteriorated over the past week

New 90-day low: CN¥7.79

New 90-day low: CN¥8.07

New 90-day low: CN¥8.22

Third quarter earnings released

First half earnings released

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥12.49

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş